Lpath, Inc. Schedules Investor Update Conference Call for Thursday, October 27, 2011 at 4:30 p.m. ET

SAN DIEGO, CA--(Marketwire - October 21, 2011) - Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based antibody therapeutics, will hold a conference call on Thursday, October 27, 2011 at 4:30 p.m. Eastern time to provide a status update and to outline the company's near-term goals.

Lpath President and CEO Scott Pancoast will host the presentation, followed by a question and answer period.

     Date: Thursday, October 27, 2011                                       
     Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)                  
     Dial-in number: 1-877-941-1429                                         
     International dial-in: 1-480-629-9857                                  
     Conference ID number: 4483219                                          

Internet simulcast and replay: http://viavid.net/dce.aspx?sid=00008EC1

Please call the conference telephone number 5-10 minutes prior to the start time. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.

A telephone replay of the call will be available after 7:30 p.m. Eastern time on the same day and until November 27, 2011.

     Toll-free replay number: 1-877-870-5176                                
     International replay number: 1-858-384-5517                            
     Replay pin number: 4483219                                             

About Lpath
San Diego-based Lpath, a therapeutic antibody company, is the category leader in lipidomics-based antibody therapeutics, an emerging field of medicine that targets bioactive signaling lipids for treating a wide range of human disease. Lpath's ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company has developed three drug candidates, one of which (iSONEP™ for wet AMD) has initiated mid-stage clinical trials and another of which (ASONEP™ for cancer) will soon begin mid-stage clinical trials. The third candidate is a pre-clinical anti-LPA antibody, which has shown efficacy in animal models of fibrosis, pain, neurotrauma, and ocular disease. Lpath entered into an agreement with Pfizer (NYSE: PFE) in 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP. For more information, visit www.Lpath.com.

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati: Lipidomics wet-AMD antibodies disease-promoting bioactive lipids drug-discovery platform S1P